Addition of eplerenone to an angiotensin-converting enzyme inhibitor effectively improves nitric oxide bioavailability

Hypertension

Volumn 51, Issue 3, 2008, Pages 734-741

  Imanishi, Toshio ^a   Ikejima, Hideyuki ^a   Tsujioka, Hiroto ^a   Kuroi, Akio ^a   Kobayashi, Katsunobu ^a   Muragaki, Yasuteru ^a   Mochizuki, Seiichi ^b   Goto, Masami ^b   Yoshida, Kiyoshi ^b   Akasaka, Takashi ^a  

^a WAKAYAMA MEDICAL UNIVERSITY   (Japan)

^b KAWASAKI MEDICAL SCHOOL   (Japan)

Author keywords

Aldosterone; Endothelial function; Nitrosative stress; NO

Indexed keywords

3 NITROTYROSINE; ACETYLCHOLINE; ENALAPRIL; EPLERENONE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PEROXYNITRITE; REACTIVE OXYGEN METABOLITE; SUPEROXIDE; TETRAHYDROBIOPTERIN;

ADD ON THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROSIS; BIOAVAILABILITY; BIOSYNTHESIS; BLOOD PRESSURE MEASUREMENT; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DISEASE MARKER; DRUG EFFICACY; DRUG POTENTIATION; ENZYME ACTIVITY; EXPERIMENTAL RABBIT; HEART INFARCTION; HISTOPATHOLOGY; HYPERLIPIDEMIA; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUANTITATIVE ANALYSIS; THORACIC AORTA; TREATMENT DURATION; VASCULAR ENDOTHELIUM;

ACETYLCHOLINE; ALDOSTERONE; ALDOSTERONE ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; AORTA, THORACIC; ATHEROSCLEROSIS; BIOLOGICAL AVAILABILITY; BLOOD PRESSURE; CHOLESTEROL; ENALAPRIL; NITRIC OXIDE; PEPTIDYL-DIPEPTIDASE A; PEROXYNITROUS ACID; RABBITS; REACTIVE OXYGEN SPECIES; SPIRONOLACTONE;

EID: 39749139508     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.107.104299     Document Type: Article

References (31)

1. Imanishi T, Kobayashi K, Kuroi A, Mochizuki S, Goto M, Yoshida K, Akasaka T. Effects of angiotensin II on NO bioavailability evaluated using a catheter-type NO sensor. Hypertension. 2006;48:1058-1065.
2. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342:145-153.
3. Duprez DA, De Buyzere ML, Rietzschel ER, Taes Y, Clement DL, Morgan D, Cohn JN. Inverse relationship between aldosterone and large artery compliance in chronically treated heart failure patients. Eur Heart J. 1998;31:451-458.
4. Borghi C, Boschi S, Ambrosioni E, Melandri G, Branzi A, Magnami B. Evidence of a partial escape of renin-angiotensin-aldosterone blockade in patients with acute myocardial infarction. J Clin Pharmacol. 1993;33:44-45.
5. Virdis A, Neves MF, Amiri F, Viel E, Touyz RM, Schiffrin EL. Spironolactone improves angiotensin-induced vascular changes and oxidative stress. Hypertension. 2002;40:504-510.
6. Rajagopalan S, Duquaine D, King S, Pitt B, Patel P. Mineralcorticoid receptor antagonism in experimental atherosclerosis. Circulation. 2002;105:2212-2216.
7. Blanco-Rivero J, Cachofeiro V, Lahera V, Aras-Lopez R, Marquez-Rodas I, Salaices M, Xavier FE, Ferrer M, Balfagon G. Participation of prostacyclin in endothelial dysfunction induced by aldosterone in normotensive and hypertensive rats. Hypertension. 2005;46:107-112.
8. Mochizuki S, Miyasaka T, Goto M, Ogasawara Y, Yada T, Akiyama M, Neishi Y, Toyoda T, Tomita J, Koyama Y, Tsujioka K, Kajiya F, Akasaka T, Yoshida K. Measurement of acetylcholine-induced endothelium-derived nitric oxide in aorta using a newly developed catheter-type nitric oxide sensor. Biochem Biophy Res Commun. 2003;306:505-508.
9. Neishi Y, Mochizuki S, Miyasaka T, Kawamoto T, Kume T, Sukmawan R, Tsukiji M, Ogasawara Y, Kajiya F, Akasaka T, Yoshida K, Goto M. Evaluation of bioavailability of nitric oxide in coronary circulation by direct measurement of plasma nitric oxide concentration. Proc Natl Acad Sci U S A. 2005;102:11456-11461.
10. Hoshida S, Nishida M, Yamashita N, Igarashi J, Aoki K, Hori M, Kuzuya T, Tada M. Vascular angiotensin-converting enzyme activity in cholesterol-fed rabbits: effects of enalapril. Atherosclerosis. 1997;130:53-59.
11. Mihailidou AS, Mardini M, Funder JW, Raison M. Mineralocorticoid and angiotensin receptor antagonism during hyperaldosterolemia. Hypertension. 2002;40:124-129.
12. Ter Steege JCA, Koster-Kamphuis L, Van Straaten EA, Forget P, Buurman WA. Nitrotyrosine in plasma of celiac disease patients as detected by a new sandwich ELISA. Free Rad Biol Med. 1998;25:953-963.
13. Rajagopalan S, Kurz S, Munzel T, Tarpey M, Freeman BA, Griendling KK, Harrison DG. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. J Clin Invest. 1996;97:1916-1923.
14. Imanishi T, McBride J, Ho Q, O'Brien KD, Schwartz SM, Han DK. Expression of cellular FLICE-inhibitory protein in human coronary arteries and in a rat vascular injury model. Am J Pathol. 2000;156:125-137.
15. Fukushima T, Nixon JC. Analysis of reduced forms of biopterin in biological tissues and fluids. Anal Biochem. 1980;102:176-188.
16. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999;341:709-717.
17. Mochizuki S, Himi N, Miyasaka T, Nakamoto H, Takemoto M, Hirano K, Tsujioka K, Ogasawara Y, Kajiya F. Evaluation of basic performance and applicability of a newly developed in vivo nitric oxide sensor. Physiol Meas. 2002;23:261-268.
18. Farquharson CA, Struthers AD. Spironolactone increases nitric oxide bioavailability, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation. 2000;101:594-597.
19. Rocha R, Chander PN, Khanna K, Zuckerman A, Stier CT Jr. Mineralcorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. Hypertension. 1998;31:451-458.
20. Griendling KK, FitzGerald GA. Oxidative stress and cardiovascular injury: Part I: basic mechanisms and in vivo monitoring of ROS. Circulation. 2003;108:1912-1916.
21. Landmesser U, Dikalov S, Price SR, McCann L, Fukai T, Holland SM, Mitch WE, Harrison DG. Oxidation of tetrahydropterin leads to uncoupling of endothelial cell nitric oxide synthesis in hypertension. J Clin Invest. 2003;111:1201-1209.
22. Bendall JK, Alp NJ, Warrick N, Cai S, Adlam D, Rockett K, Yokoyama M, Kawashima S, Channon KM. Stoichiometric relationships between endothelial tetrahydrobiopterin, endothelial NO synthase (eNOS) activity, and eNOS coupling in vivo: insights from transgenic mice with endothelial-targeted GTP cyclohydrolase 1 and eNOS overexpression. Circ Res. 2005;97:864-871.
23. Michell BJ, Chen ZP, Tiganis T, Stapleton D, Katsis F, Power DA, Power DA, Sim AT, Kemp BE. Coordinated control of endothelial nitric-oxide synthase phosphorylation by protein kinase C and the camp-dependent protein kinase. J Biol Chem. 2001;276:17625-17628.
24. Kawashima S, Yokoyama M. Dysfunction of endothelial nitric oxide synthase and atherosclerosis. Arterioscler Thromb Vasc Biol. 2004;24:998-1005.
25. Ozaki M, Kawashima S, Yamashita T, Hirase T, Namiki M, Inoue N, Hirata K, Yasui H, Sakurai H, Yoshida Y, Masada M, Yokoyama M. Overexpression of endothelial nitric oxide synthase accelerates atherosclerotic lesion formation in apo E-deficient mice. J Clin Invest. 2002;110:331-340.
26. Saruta T, Kageyama S, Ogihara T, Hiwada K, Ogawa M, Tawara K, Gatlin M, Garthwaite S, Bittman R, Patrick J. Efficacy and safety of the selective aldosterone blocker eplerenone in Japanese patients with hypertension: a randomized, double-blind, placebo-controlled, dose-ranging study. J Clin Hypertens. 2004;6:175-185.
27. Funder J. Non-genomic actions of aldosterone: role in hypertension. Curr Opin Nephrol Hypertens. 2001;10:227-230.
28. Falkenstein E, Tillmann HC, Christ M, Feuring M, Wehling M. Multiple actions of steroid hormones: a focus on rapid, nongenomic effects. Pharmacol Rev. 2000;52:513-555.
29. Fuller PJ, Young MJ. Mechanisms of mineralcorticoid action. Hypertension. 2005;46:1227-1235.
30. Nagata D, Takahashi M, Sawai K, Tagami T, Usui T, Shimatsu A, Hirata Y, Naruse M. Molecular mechanism of the inhibitory effect of aldosterone on endothelial NO synthase activity. Hypertension. 2006;48:165-171.
31. Bendall JK, Alp NJ, Warrick N, Cai S, Adlam D, Rockett K, Yokoyama M, Kawashima S, Channon KM. Stoichiometric relationships between endothelial tetrahydrobiopterin, endothelial NO synthase (eNOS), and eNOS coupling in vivo: insights from transgenic mice with endothelial-targeted GTP cyclohydrolase 1 and eNOS overexpression. Circ Res. 2005;98:864-871.